
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
“I believe that people must be tested to know what they are truly capable of. Some of the smartest and most dynamic people in business today work in healthcare marketing, and knowing this pushes me to keep up with them.” Listen to the Podcast for more coverage






